Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SRx Health Solutions (SRXH) Cash & Equivalents (2016 - 2025)

SRx Health Solutions (SRXH) has disclosed Cash & Equivalents for 13 consecutive years, with $1.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents rose 1134.91% year-over-year to $1.3 million, compared with a TTM value of $1.3 million through Sep 2025, up 1134.91%, and an annual FY2025 reading of $1.3 million, changed N/A over the prior year.
  • Cash & Equivalents was $1.3 million for Q3 2025 at SRx Health Solutions, up from $912000.0 in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $26.0 million in Q3 2021 and bottomed at $106000.0 in Q3 2024.
  • Average Cash & Equivalents over 5 years is $6.5 million, with a median of $3.8 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents surged 4526.64% in 2021, then crashed 97.21% in 2024.
  • Year by year, Cash & Equivalents stood at $21.7 million in 2021, then plummeted by 56.4% to $9.5 million in 2022, then tumbled by 52.97% to $4.5 million in 2023, then crashed by 31.18% to $3.1 million in 2024, then crashed by 57.31% to $1.3 million in 2025.
  • Business Quant data shows Cash & Equivalents for SRXH at $1.3 million in Q3 2025, $912000.0 in Q2 2025, and $1.1 million in Q1 2025.